Venus Medtech (Hangzhou)HKSE:02500 +12.50%52 Price-to-Tangible-Book is 1.54 as of Jun. 24, 2026, which is 52% below its 10-year median of 3.19. GuruFocus rates HKSE:02500 with a GF Score™ of 52/100 and a GF Value™ of HK$3.39 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 700 Medical Devices & Instruments companies, Venus Medtech (Hangzhou) ranks better than 69.57% on this metric.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s Price-to-Tangible-Book or its related term are showing as below:
HKSE:02500'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34 Med: 3.19 Max: 9.16
Current: 1.55
During the past 9 years, Venus Medtech (Hangzhou)'s highest Price to Tangible Book Ratio was 9.16. The lowest was 1.34. And the median was 3.19.
HKSE:02500's Price-to-Tangible-Book is ranked better than 69.57% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 2.6
vs HKSE:02500: 1.55
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Venus Medtech (Hangzhou) Price-to-Tangible-Book Related Terms
Venus Medtech (Hangzhou) Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Venus Medtech (Hangzhou)'s Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02500 vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Venus Medtech (Hangzhou) (HKSE:02500) has a Price-to-Tangible-Book of 1.54 as of Jun. 24, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Venus Medtech (Hangzhou) and its competitors. This is 52% below median its historical median of 3.19. Over the past decade, Venus Medtech (Hangzhou)'s Price-to-Tangible-Book has ranged from 1.34 to 9.16. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #213 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 30.4%.
Is Venus Medtech (Hangzhou)'s Price-to-Tangible-Book too high?
Venus Medtech (Hangzhou)'s current Price-to-Tangible-Book of 1.54 is 52% below median its 10-year median of 3.19. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 9.16. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.60. Venus Medtech (Hangzhou)'s value of 1.54 is 40.8% below this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #213 out of 700 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #213 out of 700 companies for Price-to-Tangible-Book. This puts Venus Medtech (Hangzhou) in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.60. Venus Medtech (Hangzhou)'s value of 1.54 is 40.8% below this benchmark. Historically, Venus Medtech (Hangzhou)'s own Price-to-Tangible-Book has ranged from 1.34 to 9.16 over the past decade. While the company's 10-year median is 3.19 vs. the industry median of 2.60, Venus Medtech (Hangzhou) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.60, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Price-to-Tangible-Book of 1.54 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Price-to-Tangible-Book is 1.54, which is 52% below median its own 10-year median of 3.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.39, compared to a current price of HK$1.35 — trading 60.2% below its estimated fair value. The current Price-to-Tangible-Book is 1.54, which is 52% below median its 10-year median of 3.19 and 40.8% below the Medical Devices & Instruments industry median of 2.60. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Price-to-Tangible-Book is 1.54 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of HK$1.35 is trading 60.2% below its estimated GF Value™ of HK$3.39.
GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.
Key valuation signals for HKSE:02500:
Price-to-Tangible-Book: 1.54 (52% below median its 10-year median of 3.19)
GF Value™: HK$3.39 vs. price of HK$1.35 (60.2% below fair value)
Industry Position: 40.8% below the Medical Devices & Instruments median (#213 of 700)
No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for HKSE:02500
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02500 has been successfully added to your 
